Patents by Inventor Chuan-Lung Hsu
Chuan-Lung Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210139592Abstract: An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 2-4, 6-8, 10-12, 14-16, or 18-20; and/or a light chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 22-24, 26-28, 30-32, 34-36, or 38-40, wherein the antibody is a chimeric, humanized, composite, or human antibody.Type: ApplicationFiled: July 14, 2019Publication date: May 13, 2021Applicant: Development Center for BiotechnologyInventors: Cheng-Chou YU, Shih-Rang YANG, Tsung-Han HSIEH, Mei-Chi CHAN, Shu-Ping YEH, Chuan-Lung HSU, Ling-Yueh HU, Chih-Lun HSIAO
-
Patent number: 10947316Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab?(L?D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.Type: GrantFiled: June 15, 2018Date of Patent: March 16, 2021Assignee: Development Center for BiotechnologyInventors: Chao-Pin Lee, Shih-Hsien Chuang, Chuan-Lung Hsu, Yi-Jen Chen, Yu-Chin Nieh, Win-Yin Wei, Chia-Cheng Wu
-
Publication number: 20190330376Abstract: A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.Type: ApplicationFiled: December 29, 2017Publication date: October 31, 2019Applicant: Development Center for BiotechnologyInventors: Chen-Li Chien, Gregory Jiann Chen, Chuan-Lung Hsu, Jei-Hwa Yu, Hsien-Yu Tsai, Show-Shan Sheu, Wei-Jung Chang, Chia-Cheng Wu
-
Publication number: 20190106507Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab?(L?D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.Type: ApplicationFiled: June 15, 2018Publication date: April 11, 2019Applicant: Development Center for BiotechnologyInventors: Chao-Pin Lee, Shih-Hsien Chuang, Chuan-Lung Hsu, Yi-Jen Chen, Yu-Chin Nieh, Win-Yin Wei, Chia-Cheng Wu
-
Patent number: 10138300Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.Type: GrantFiled: July 3, 2017Date of Patent: November 27, 2018Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Jiann-Shiun Lai, Li-Shuang Ai, Yan-Da Lai, Yen-Yu Wu, Yi-San Tsai, Yi-Jiue Tsai, Juo-Yu Huang, Cheng-Chou Yu, Chuan-Lung Hsu, Chien-Tsun Kuan, Szu-Liang Lai, Li-Ya Wang
-
Publication number: 20180186884Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.Type: ApplicationFiled: July 3, 2017Publication date: July 5, 2018Inventors: JIANN-SHIUN LAI, Li-Shuang Ai, Yan-Da Lai, Yen-Yu Wu, Yi-San Tsai, Yi-Jiue Tsai, Juo-Yu Huang, Cheng-Chou Yu, Chuan-Lung Hsu, Chien-Tsun Kuan, Szu-Liang Lai, Li-Ya Wang
-
Publication number: 20170369525Abstract: A method for specific linkage to a glycoprotein includes obtaining a glycoprotein having a monoglycan or diglycan attached thereto; producing a reactive functional group on a sugar unit on the glycoprotein; and coupling a linker or a payload to the reactive functional group on the glycoprotein.Type: ApplicationFiled: December 31, 2015Publication date: December 28, 2017Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Chao-Pin Lee, Cheng-Chou Yu, Chi-Huey Wong, Chuan-Lung Hsu, Chun-Chung Lee, Shih-Hsien Chuang, Ta-Tung Yuan, Yi-Jen Chen, Yu-Chin Nieh
-
Publication number: 20170233480Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.Type: ApplicationFiled: December 29, 2016Publication date: August 17, 2017Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: JIANN-SHIUN LAI, LI-SHUANG AI, YAN-DA LAI, YEN-YU WU, YI-SAN TSAI, YI-JIUE TSAI, JUO-YU HUANG, CHENG-CHOU YU, CHUAN-LUNG HSU, CHIEN-TSUN KUAN, SZU-LIANG LAI, LI-YA WANG
-
Patent number: 9447193Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.Type: GrantFiled: March 24, 2014Date of Patent: September 20, 2016Assignees: Development Center for Biotechnology, Academia Sinica, Chang Gung Memorial HospitalInventors: Alice L. Yu, John Yu, Ya-Hui Wang, Chuan-Lung Hsu, Yi-Chang Chen, Ying-Yung Lok
-
Publication number: 20140363372Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.Type: ApplicationFiled: March 24, 2014Publication date: December 11, 2014Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, CHANG GUNG MEMORIAL HOSPITAL, ACADEMIA SINICAInventors: Alice L. Yu, John Yu, Ya-Hui Wang, Chuan-Lung Hsu, Yi-Chang Chen, Ying-Yung Lok